CHMP: AMT's Glybera, Europe's first gene therapy, still not approvable
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has maintained its earlier opinion on Amsterdam Molecular Therapeutics' Glybera (alipogene tiparvovec), saying it is still not approvable at this time.